{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:40:25Z","timestamp":1790224825002,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>DXd, a camptothecin derivative, is employed as the payload molecule for the antibody\u2013drug conjugate (ADC) trastuzumab deruxtecan (T-DXd), which is in current clinical use for the treatment of breast and gastric cancer. Despite the clinical success of ADCs for treatment of cancer, exposure to released payload in plasma and extracellular fluids contributes to off-target toxicities, which limit ADC dosage and efficacy. In this study, we evaluated an anti-DXd antibody fragment, 8C2 Fab, for utility in mitigating DXd toxicity in cell culture and for improving the therapeutic index of T-DXd <jats:italic>in vivo<\/jats:italic> in mice. 8C2 Fab was produced, purified, and characterized for binding to DXd and T-DXd. <jats:italic>In vitro<\/jats:italic> competitive cytotoxicity assays showed that 8C2 Fab blocked the cell-killing effect of DXd, increasing the DXd concentration associated with 50% growth inhibition (IC<jats:sub>50<\/jats:sub>) by 50-fold; however, 8C2 did not decrease the cytotoxicity of T-DXd. Co-administration of 8C2 Fab to mice with 600\u00a0mg\/kg T-DXd significantly decreased the percentage body weight loss at nadir in mice compared to results found with T-DXd alone (12.8\u2009\u00b1\u20093.66% <jats:italic>vs<\/jats:italic> 7.08\u2009\u00b1\u20094.24%, <jats:italic>p<\/jats:italic>\u2009=\u20090.0331). In contrast, co-administration of 8C2 Fab with T-DXd (1 or 10\u00a0mg\/kg) did not negatively impact the anti-tumor efficacy in mice bearing NCI-N87 xenograft tumors. Our results demonstrate that 8C2 Fab decreases DXd cytotoxicity <jats:italic>in vitro<\/jats:italic>, and decreases T-DXd-induced toxicity <jats:italic>in vivo<\/jats:italic>, while not inhibiting T-DXd anti-tumor efficacy <jats:italic>in vitro<\/jats:italic> or <jats:italic>in vivo<\/jats:italic>, supporting utility for improving the therapeutic index of T-DXd.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical Abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1208\/s12248-025-01087-w","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T20:08:06Z","timestamp":1749067686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Improving the Therapeutic Selectivity of Trastuzumab Deruxtecan Using 8C2 Fab Fragments"],"prefix":"10.1208","volume":"27","author":[{"given":"Jue","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon M.","family":"Bordeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6340-9370","authenticated-orcid":false,"given":"Joseph P.","family":"Balthasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"12","key":"1087_CR1","first-page":"2350","volume":"7","author":"F Li","year":"2017","unstructured":"Li F, Jiang T, Li Q, Ling X. Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer? Am J Cancer Res. 2017;7(12):2350\u201394.","journal-title":"Am J Cancer Res"},{"issue":"5","key":"1087_CR2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40265-020-01281-4","volume":"80","author":"SJ Keam","year":"2020","unstructured":"Keam SJ. Trastuzumab deruxtecan: first approval. Drugs. 2020;80(5):501\u20138. https:\/\/doi.org\/10.1007\/s40265-020-01281-4.","journal-title":"Drugs"},{"issue":"10","key":"1087_CR3","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY. Sacituzumab govitecan: first approval. Drugs. 2020;80(10):1019\u201325. https:\/\/doi.org\/10.1007\/s40265-020-01337-5.","journal-title":"Drugs"},{"issue":"1","key":"1087_CR4","doi-asserted-by":"publisher","first-page":"1951427","DOI":"10.1080\/19420862.2021.1951427","volume":"13","author":"AQ Dean","year":"2021","unstructured":"Dean AQ, Luo S, Twomey JD, Zhang B. Targeting cancer with antibody-drug conjugates: promises and challenges. MAbs. 2021;13(1):1951427. https:\/\/doi.org\/10.1080\/19420862.2021.1951427.","journal-title":"MAbs"},{"issue":"4","key":"1087_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","volume":"8","author":"H Donaghy","year":"2016","unstructured":"Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs. 2016;8(4):659\u201371. https:\/\/doi.org\/10.1080\/19420862.2016.1156829.","journal-title":"MAbs"},{"issue":"19","key":"1087_CR6","doi-asserted-by":"publisher","first-page":"6722","DOI":"10.1158\/1078-0432.Ccr-04-0721","volume":"10","author":"N Masubuchi","year":"2004","unstructured":"Masubuchi N, May RD, Atsumi R. A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte\/macrophage assay. Clin Cancer Res. 2004;10(19):6722\u201331. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-04-0721.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1087_CR7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s002800050807","volume":"42","author":"E Kumazawa","year":"1998","unstructured":"Kumazawa E, Jimbo T, Ochi Y, Tohgo A. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice. Cancer Chemother Pharmacol. 1998;42(3):210\u201320.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"17","key":"1087_CR8","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1200\/jco.2000.18.17.3151","volume":"18","author":"EK Rowinsky","year":"2000","unstructured":"Rowinsky EK, Johnson TR, Geyer CE Jr, Hammond LA, Eckhardt SG, Drengler R, et al. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol. 2000;18(17):3151\u201363. https:\/\/doi.org\/10.1200\/jco.2000.18.17.3151.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1087_CR9","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2019","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2019;382(7):610\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1914510.","journal-title":"N Engl J Med"},{"issue":"19","key":"1087_CR10","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1002\/cncr.30789","volume":"123","author":"AJ Ocean","year":"2017","unstructured":"Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. Cancer. 2017;123(19):3843\u201354. https:\/\/doi.org\/10.1002\/cncr.30789.","journal-title":"Cancer"},{"issue":"2","key":"1087_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cncr.34507","volume":"129","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Liu K, Wang K, Zhu H. Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. Cancer. 2023;129(2):283\u201395. https:\/\/doi.org\/10.1002\/cncr.34507.","journal-title":"Cancer"},{"key":"1087_CR12","doi-asserted-by":"publisher","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers (Basel). 2023;15(3). https:\/\/doi.org\/10.3390\/cancers15030713.","DOI":"10.3390\/cancers15030713"},{"key":"1087_CR13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","volume":"200","author":"PK Mahalingaiah","year":"2019","unstructured":"Mahalingaiah PK, Ciurlionis R, Durbin KR, Yeager RL, Philip BK, Bawa B, et al. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol Ther. 2019;200:110\u201325. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.04.008.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1087_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93. https:\/\/doi.org\/10.1038\/s41392-022-00947-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"1087_CR15","doi-asserted-by":"publisher","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","volume":"7","author":"CA Powell","year":"2022","unstructured":"Powell CA, Modi S, Iwata H, Takahashi S, Smit EF, Siena S, et al. Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 2022;7(4):100554. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100554.","journal-title":"ESMO Open"},{"issue":"12","key":"1087_CR16","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","volume":"7","author":"P Tarantino","year":"2021","unstructured":"Tarantino P, Modi S, Tolaney SM, Cort\u00e9s J, Hamilton EP, Kim S-B, et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review. JAMA Oncol. 2021;7(12):1873\u201381. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3595.","journal-title":"JAMA Oncol"},{"issue":"4","key":"1087_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1158\/1535-7163.MCT-22-0440","volume":"22","author":"BM Bordeau","year":"2023","unstructured":"Bordeau BM, Nguyen TD, Polli JR, Chen P, Balthasar JP. Payload-binding Fab fragments increase the therapeutic index of MMAE antibody-drug conjugates. Mol Cancer Ther. 2023;22(4):459\u201370. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0440.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"1087_CR18","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S0022-3565(25)39006-3","volume":"268","author":"J Balthasar","year":"1994","unstructured":"Balthasar J, Fung HL. Utilization of antidrug antibody fragments for the optimization of intraperitoneal drug therapy: studies using digoxin as a model drug. J Pharmacol Exp Ther. 1994;268(2):734\u20139.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"1087_CR19","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1021\/js960135w","volume":"85","author":"JP Balthasar","year":"1996","unstructured":"Balthasar JP, Fung HL. Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments. J Pharm Sci. 1996;85(10):1035\u201343. https:\/\/doi.org\/10.1021\/js960135w.","journal-title":"J Pharm Sci"},{"issue":"1\u20132","key":"1087_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ijpharm.2014.01.038","volume":"465","author":"DK Shah","year":"2014","unstructured":"Shah DK, Balthasar JP. PK\/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice. Int J Pharm. 2014;465(1\u20132):228\u201338. https:\/\/doi.org\/10.1016\/j.ijpharm.2014.01.038.","journal-title":"Int J Pharm"},{"issue":"1","key":"1087_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10928-013-9346-9","volume":"41","author":"DK Shah","year":"2014","unstructured":"Shah DK, Balthasar JP. Predicting the effects of 8C2, a monoclonal anti-topotecan antibody, on plasma and tissue disposition of topotecan. J Pharmacokinet Pharmacodyn. 2014;41(1):55\u201369. https:\/\/doi.org\/10.1007\/s10928-013-9346-9.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"9","key":"1087_CR22","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1002\/jps.20422","volume":"94","author":"ED Lobo","year":"2005","unstructured":"Lobo ED, Balthasar JP. Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. J Pharm Sci. 2005;94(9):1957\u201364.","journal-title":"J Pharm Sci"},{"issue":"8","key":"1087_CR23","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1002\/jps.10432","volume":"92","author":"ED Lobo","year":"2003","unstructured":"Lobo ED, Soda DM, Balthasar JP. Application of pharmacokinetic-pharmacodynamic modeling to predict the kinetic and dynamic effects of anti-methotrexate antibodies in mice. J Pharm Sci. 2003;92(8):1665\u201376. https:\/\/doi.org\/10.1002\/jps.10432.","journal-title":"J Pharm Sci"},{"key":"1087_CR24","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-22-0804","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP. Use of payload binding selectivity enhancers to improve therapeutic index of maytansinoid-antibody-drug conjugates. Mol Cancer Ther. 2023. https:\/\/doi.org\/10.1158\/1535-7163.Mct-22-0804.","journal-title":"Mol Cancer Ther"},{"key":"1087_CR25","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/9780470117118.ch06e","volume-title":"Handbook of pharmaceutical biotechnology","author":"J Chen","year":"2007","unstructured":"Chen J, Balthasar JP. Development and characterization of high-affinity anti-topotecan IgG and Fab fragments. In: Gad SC, editor. Handbook of pharmaceutical biotechnology. Hoboken: John Wiley & Sons, Inc.; 2007. p. 835\u201350."},{"issue":"6","key":"1087_CR26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/ppo.0000000000000627","volume":"28","author":"MA Gouda","year":"2022","unstructured":"Gouda MA, Subbiah V. Strategies for mitigating antibody-drug conjugate related adverse events for precision therapy. Cancer J. 2022;28(6):496\u2013507. https:\/\/doi.org\/10.1097\/ppo.0000000000000627.","journal-title":"Cancer J"},{"issue":"1","key":"1087_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","volume":"36","author":"JC Masters","year":"2018","unstructured":"Masters JC, Nickens DJ, Xuan D, Shazer RL, Amantea M. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Invest New Drugs. 2018;36(1):121\u201335. https:\/\/doi.org\/10.1007\/s10637-017-0520-6.","journal-title":"Invest New Drugs"},{"issue":"5","key":"1087_CR28","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/cncr.11557","volume":"98","author":"FJ Esteva","year":"2003","unstructured":"Esteva FJ, Rivera E, Cristofanilli M, Valero V, Royce M, Duggal A, et al. A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer. 2003;98(5):900\u20137. https:\/\/doi.org\/10.1002\/cncr.11557.","journal-title":"Cancer"},{"key":"1087_CR29","doi-asserted-by":"publisher","first-page":"104398","DOI":"10.1016\/j.phrs.2019.104398","volume":"148","author":"C Bailly","year":"2019","unstructured":"Bailly C. Irinotecan: 25 years of cancer treatment. Pharmacol Res. 2019;148:104398. https:\/\/doi.org\/10.1016\/j.phrs.2019.104398.","journal-title":"Pharmacol Res"},{"key":"1087_CR30","doi-asserted-by":"publisher","unstructured":"Tamura K, Modi S, Tsurutani J, Takahashi S, Krop I, Iwata H, et al. Abstract P6\u201317\u201310: dose justification for DS-8201a, a HER2-targeted antibody-drug conjugate, for HER2-positive breast cancer: observed clinical data and exposure-response analyses. Cancer Res. 2019;79(4_Supplement):P6\u201317\u20130-P6--0. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs18-p6-17-10.","DOI":"10.1158\/1538-7445.Sabcs18-p6-17-10"},{"issue":"5","key":"1087_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corva\u00efa N. Strategies and challenges for the next generation of antibody\u2013drug conjugates. Nat Rev Drug Discov. 2017;16(5):315\u201337. https:\/\/doi.org\/10.1038\/nrd.2016.268.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"1087_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4155\/tde-2016-0002","volume":"7","author":"M Vankemmelbeke","year":"2016","unstructured":"Vankemmelbeke M, Durrant L. Third-generation antibody drug conjugates for cancer therapy \u2013 a balancing act. Ther Deliv. 2016;7(3):141\u20134. https:\/\/doi.org\/10.4155\/tde-2016-0002.","journal-title":"Ther Deliv"},{"issue":"6","key":"1087_CR33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1502000","volume":"373","author":"CV Pollack Jr","year":"2015","unstructured":"Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1502000.","journal-title":"N Engl J Med"},{"issue":"15","key":"1087_CR34","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/nejm197604082941501","volume":"294","author":"TW Smith","year":"1976","unstructured":"Smith TW, Haber E, Yeatman L, Butler VP Jr. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med. 1976;294(15):797\u2013800. https:\/\/doi.org\/10.1056\/nejm197604082941501.","journal-title":"N Engl J Med"},{"key":"1087_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.toxicon.2018.03.004","volume":"146","author":"AH Laustsen","year":"2018","unstructured":"Laustsen AH, Mar\u00eda Guti\u00e9rrez J, Knudsen C, Johansen KH, Berm\u00fadez-M\u00e9ndez E, Cerni FA, et al. Pros and cons of different therapeutic antibody formats for recombinant antivenom development. Toxicon. 2018;146:151\u201375. https:\/\/doi.org\/10.1016\/j.toxicon.2018.03.004.","journal-title":"Toxicon"},{"issue":"2","key":"1087_CR36","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S0022-3565(25)39006-3","volume":"268","author":"J Balthasar","year":"1994","unstructured":"Balthasar J, Fung HL. Utilization of antidrug antibody fragments for the optimization of intraperitoneal drug therapy: studies using digoxin as a model drug. J Pharmacol Exp Ther. 1994;268(2):734\u20139.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20132","key":"1087_CR37","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jchromb.2004.11.035","volume":"816","author":"J Chen","year":"2005","unstructured":"Chen J, Balthasar JP. High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;816(1\u20132):183\u201392. https:\/\/doi.org\/10.1016\/j.jchromb.2004.11.035.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"5","key":"1087_CR38","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1080\/09168451.2014.993354","volume":"79","author":"HN Song","year":"2015","unstructured":"Song HN, Kim DH, Park SG, Lee MK, Paek SH, Woo EJ. Purification and characterization of Fab fragments with rapid reaction kinetics against myoglobin. Biosci Biotechnol Biochem. 2015;79(5):718\u201324. https:\/\/doi.org\/10.1080\/09168451.2014.993354.","journal-title":"Biosci Biotechnol Biochem"},{"issue":"5","key":"1087_CR39","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1006\/jmbi.1994.1691","volume":"243","author":"JP Derrick","year":"1994","unstructured":"Derrick JP, Wigley DB. The third IgG-binding domain from streptococcal protein G. An analysis by X-ray crystallography of the structure alone and in a complex with Fab. J Mol Biol. 1994;243(5):906\u201318. https:\/\/doi.org\/10.1006\/jmbi.1994.1691.","journal-title":"J Mol Biol."},{"issue":"1","key":"1087_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/0023677219883319","volume":"54","author":"SR Talbot","year":"2020","unstructured":"Talbot SR, Biernot S, Bleich A, van Dijk RM, Ernst L, H\u00e4ger C, et al. Defining body-weight reduction as a humane endpoint: a critical appraisal. Lab Anim. 2020;54(1):99\u2013110. https:\/\/doi.org\/10.1177\/0023677219883319.","journal-title":"Lab Anim"},{"issue":"3","key":"1087_CR41","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.yrtph.2015.10.018","volume":"73","author":"F Sewell","year":"2015","unstructured":"Sewell F, Ragan I, Marczylo T, Anderson B, Braun A, Casey W, et al. A global initiative to refine acute inhalation studies through the use of \u2018evident toxicity\u2019 as an endpoint: towards adoption of the fixed concentration procedure. Regul Toxicol Pharmacol. 2015;73(3):770\u20139. https:\/\/doi.org\/10.1016\/j.yrtph.2015.10.018.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"8","key":"1087_CR42","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1002\/ijc.30870","volume":"141","author":"N Takegawa","year":"2017","unstructured":"Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, et al. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J Cancer. 2017;141(8):1682\u20139. https:\/\/doi.org\/10.1002\/ijc.30870.","journal-title":"Int J Cancer"},{"issue":"7","key":"1087_CR43","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039\u201346. https:\/\/doi.org\/10.1111\/cas.12966.","journal-title":"Cancer Sci"},{"issue":"2","key":"1087_CR44","first-page":"135","volume":"61","author":"N Masubuchi","year":"2006","unstructured":"Masubuchi N. Risk assessment of human myelotoxicity of anticancer drugs: a predictive model and the in vitro colony forming unit granulocyte\/macrophage (CFU-GM) assay. Pharmazie. 2006;61(2):135\u20139.","journal-title":"Pharmazie"},{"issue":"5","key":"1087_CR45","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s002800050600","volume":"39","author":"CL Erickson-Miller","year":"1997","unstructured":"Erickson-Miller CL, May RD, Tomaszewski J, Osborn B, Murphy MJ, Page JG, et al. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother Pharmacol. 1997;39(5):467\u201372. https:\/\/doi.org\/10.1007\/s002800050600.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"1087_CR46","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1080\/00498254.2020.1755909","volume":"50","author":"H Okamoto","year":"2020","unstructured":"Okamoto H, Oitate M, Hagihara K, Shiozawa H, Furuta Y, Ogitani Y, et al. Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice. Xenobiotica. 2020;50(10):1242\u201350. https:\/\/doi.org\/10.1080\/00498254.2020.1755909.","journal-title":"Xenobiotica"},{"issue":"6","key":"1087_CR47","first-page":"1517","volume":"54","author":"LT Baxter","year":"1994","unstructured":"Baxter LT, Zhu H, Mackensen DG, Jain RK. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 1994;54(6):1517\u201328.","journal-title":"Cancer Res"},{"key":"1087_CR48","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10928-019-09639-2","volume":"46","author":"Z Li","year":"2019","unstructured":"Li Z, Shah DK. Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics. J Pharmacokinet Pharmacodyn. 2019;46:305\u201318.","journal-title":"J Pharmacokinet Pharmacodyn"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01087-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01087-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01087-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T13:51:56Z","timestamp":1751637116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01087-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["1087"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01087-w","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.P.B. and B.M.B. are founders of Abceutics, Inc. which is pursuing development of payload binding agents to enhance the therapeutic selectivity of antibody\u2013drug conjugates. J.P.B. and B.M.B. have financial interest through WO2021113740 A1. J.P.B. serves as the Director of the University at Buffalo Center for Protein Therapeutics, which is supported by an industry consortium. Through the consortium, J.P.B. has received research support, for work unrelated to this report, from Abbvie, Amgen, AstraZeneca, CSL-Behring, Eli Lilly, Genentech, GSK, Janssen, Merck, Roche, Sanofi, and Seagen. During the course of this work, J.P.B. has received consulting fees from companies involved with the development of cancer therapies, including: Abbvie, Amgen, Eli Lilly, Merck, and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"106"}}